Therapeutic Advancements Driving Diabetic Nephropathy Market Growth at a 5.2% CAGR

Diabetic nephropathy market was valued at $3,177.9 million in 2025 and is projected to reach $5,515.8 million by 2035, growing at a CAGR of 5.2% during the forecast period (2026-2035). The Diabetic Nephropathy market is driven by rising diabetes prevalence, early diagnosis, expanding healthcare programs, and increasing chronic disease management. Therapeutic advancements including SGLT2 inhibitors, GLP-1 receptor agonists, and nsMRAs like Finerenone—are the key growth driver, offering improved kidney protection, reduced proteinuria, and better cardiovascular outcomes, fueling global market adoption.

Browse the full report description of “Diabetic Nephropathy Market Size, Share & Trends Analysis Report by Indication (Diabetes Type-1, and Diabetes Type-2), By Diagnosis (Urine Test, Imaging Test, Blood Test, Renal Function Test, and Renal Biopsy), and By Treatment (Medications, Kidney Dialysis, Kidney Transplant), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/diabetic-nephropathy-market

Therapeutic Advancements as the Key Growth Driver in the Diabetic Nephropathy Market

SGLT2 inhibitors help protect kidney function in diabetic patients by reducing glucose reabsorption in the kidneys, lowering blood sugar levels, and decreasing proteinuria, thereby slowing the progression to end-stage renal disease. Additionally, these drugs offer cardiovascular benefits, which are particularly important for diabetic patients at high risk of heart complications.

GLP-1 receptor agonists complement this effect by reducing inflammation and oxidative stress in kidney tissues, improving glycemic control, and supporting weight reduction, which further aids in overall diabetes management.

The triple-pillar and quad-pillar therapy is also transforming the diabetic nephropathy landscape. This therapy combines SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists (nsMRAs) like Finerenone. This multi-drug approach delivers additive efficacy. For instance, results from the CONFIDENCE Trial (2025) showed that the combination of Finerenone and Empagliflozin reduced albuminuria by an additional 30% compared to either drug alone. Another key advantage is hyperkalemia mitigation: SGLT2 inhibitors help lower the risk of high potassium levels, a common side effect of other kidney drugs, making the overall regimen safer and improving patient adherence.

Overall, these therapeutic advancements are a major driver of the diabetic nephropathy market. By offering more effective kidney protection, improving cardiovascular outcomes, and enabling safer combination therapies, these innovations are increasing patient adoption, fueling demand for advanced treatment options, and expanding market growth globally.

Key Developments in the Diabetic Nephropathy Market

• In June?2025, Bayer AG released late?breaking data from its Phase?II CONFIDENCE study showing that simultaneous initiation of finerenone (Kerendia) and the SGLT2 inhibitor empagliflozin significantly reduced urine albumin?to?creatinine ratio (UACR) in patients with chronic kidney disease (CKD) associated with type?2 diabetes compared to either drug alone. These findings were presented at the 62nd European Renal Association (ERA) Congress 2025.

• In January 2025, The U.S. Food and Drug Administration (FDA) approved Novo Nordisk’s Ozempic (semaglutide) with an expanded indication to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type?2 diabetes and chronic kidney disease (CKD). This makes Ozempic the first GLP?1 receptor agonist formally recognized for slowing kidney disease progression alongside its glycemic and cardiovascular benefits, offering a major therapeutic boost for diabetic nephropathy care.

• In November 2024, Palatin Technologies, Inc. announced positive Phase?2b data at the National Kidney Foundation Spring Meeting showing a novel melanocortin agonist candidate significantly improved key kidney function markers (e.g., >30% reduction in urinary protein) in patients with Type?2 diabetic kidney disease. These promising results support further development of new mechanisms beyond current therapies.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Indication
• Diagnosis
• Treatment
• Competitive Landscape – AstraZeneca PLC, Bayer AG, Novartis AG, Pfizer Inc., and Sanofi S.A.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Diabetic Nephropathy Market Report Segment

By Indication

• Diabetes Type-1
• Diabetes Type-2

By Diagnosis

• Urine Test
• Imaging Test
• Blood Test
• Renal Function Test
• Renal Biopsy

By Treatment

• Medications
• Kidney Dialysis
• Kidney Transplant

Global Diabetic Nephropathy Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/diabetic-nephropathy-market